Cytta CORP 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OTC.Pink
Cytta Corp. filed an amendment to its 8-K disclosing a disagreement with its former auditor, Sadler, Gibb & Associates, regarding accounting treatments for convertible notes and warrants.
OTC.Pink
Cytta Corp. announced the dismissal of Sadler, Gibb and Associates, LLC and the appointment of RBSM LLP as its new independent registered public accounting firm.
OTC.Pink
Cytta Corp. announced it will restate its December 31, 2024 interim financial statements due to a $36,976 revenue recognition error from unverified sales orders.
OTC.Pink
Cytta Corp. has entered a new agreement with Genesys Technologies to integrate advanced Wi-VHFi mobile broadband technology into its Cytta Labs incubator, while also disclosing a restatement of its December 2024 financial statements due to a revenue recognition error.
OTC.Pink
Cytta Corp.'s former auditor, Prager Metis CPAs, LLC, has publicly disagreed with the company's statements in a recent 8-K filing, citing materially misstated financial statements due to fraudulent sales orders and a lack of access to critical review materials.
OTC.Pink
Cytta Corp. has dismissed its independent registered public accounting firm, Prager Metis CPAs, LLC, citing the cost of an additional forensic audit required to investigate fraudulent sales orders, despite the company's own review confirming the fraud.
OTC.Pink
Cytta Corp. has terminated a material agreement with Michael Elliott due to fraudulent sales orders, leading to the reversal of previously reported revenues and a decision to seek new auditors after a dispute over forensic audit requirements.